The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, reaching US$ 13.28 ...

The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

WUXI BIO (02269.HK) opened 3.6% higher at $17.5 today (14th). It last stood at $17.8, up 5.33%, with 12.7161 million shares traded, involving $223 million. The presentation of the company's 2025 ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in Ireland to US drugs giant Merck Sharp & Dohme for around USD500 million. WuXi ...

STA Pharmaceutical Hong Kong Investment, the shareholder of WUXI XDC (02268.HK), placed 37.8 million shares of the company at $30.855-31.515 per share, a discount of 4.5-6.5% to last Friday's ...

Merck, known as MSD outside of the United States and Canada ... The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...